 |
|
|
|
 |
|
|
| Article 1 to 7 out of 7 concerning Genaissance Pharmaceuticals, Inc.
|
-
Genaissance Will Provide Genotyping Services for Cyprus Scrapie Contract
(25 Aug 2005)
Genaissance Pharmaceuticals, Inc. announced that it will provide its high-throughput genotyping services to Biotronics Ltd., headquartered in Nicosia, Cyprus, which has been awarded a contract by the Veterinary Services in the Ministry of ...
-
Genaissance and ParAllele BioScience Sign License and Co-Marketing Agreement
(11 Apr 2005)
Genaissance Pharmaceuticals, Inc. and ParAllele BioScience, Inc. announced a joint license and co-marketing agreement to provide genetic screening technology and services for drug development and marketing. Under the terms of the agreement, ...
-
Genaissance Allowed Patent for Method of Testing Individuals for Genetic Predisposition to Reduced Metabolism of Drugs
(15 Mar 2005)
Genaissance Pharmaceuticals, Inc. has received a notice of allowance from the U.S. Patent and Trademark Office. The allowed patent, which is co-owned with Duke University, claims testing for a common genetic variant in the CYP3A4 gene to predict ...
-
Genaissance And Monsanto Company Team Up With The USDA To Map Soybean Genome
(11 Mar 2005)
An agreement between Genaissance Pharmaceuticals, Inc., Monsanto Company and the Agricultural Research Service (ARS), the chief scientific research agency of the U.S. Department of Agriculture (USDA), is expected to provide U.S. soybean plant ...
-
Genaissance Obtains License to Vanderbilt Patent Linking Genetics to Key Drug Safety Issue
(31 Jan 2005)
Genaissance Pharmaceuticals, Inc., a leading developer and user of genetic information to help guide medical therapy, expanded its ability to provide genetic tests for critical variants of key cardiac ion channel proteins involved in drug-induced ...
-
Genaissance Pharmaceuticals Enters Into HAP(TM) Technology License Agreement With Novo Nordisk
(18 Dec 2003)
Genaissance Pharmaceuticals, Inc. announced that it has licensed its HAP(TM) Technology to Novo Nordisk A/S for use in a drug development program. Under the terms of the agreement, Novo Nordisk will pay Genaissance license and service fees, ...
-
Genaissance Pharmaceuticals and AstraZeneca sign pharmacogenomics based agreement
(15 Sep 2003)
Agreement continues the commercialization of the STRENGTH study
Genaissance Pharmaceuticals, Inc. announced that it has entered into a licensing agreement with AstraZeneca PLC to utilize information generated from Genaissance's Statin Response Examined by Genetic Haplotype Markers (STRENGTH) study. Under the ...
|
|
|
|
|
Top
